This drug is contraindicated to the following patients: Patients using other MAO inhibitors (eg, selegiline hydrochloride, rasagiline mesilate) [see Contraindications for Co-administration (Do not co-administered with the following.) under Interactions].
Patients using pethidine hydrochloride-containing products, tramadol hydrochloride-containing products, or tapentadol hydrochloride [see Contraindications for Co-administration (Do not co-administered with the following.) under Interactions].
Patients using tricyclic antidepressants (eg, amitriptyline hydrochloride, amoxapine, imipramine hydrochloride, clomipramine hydrochloride, dosulepin hydrochloride, trimipramine maleate, nortriptyline hydrochloride, lofepramine hydrochloride), tetracyclic antidepressants (eg, maprotiline hydrochloride, mianserin hydrochloride, setiptiline maleate), selective serotonin reuptake inhibitors (eg, fluvoxamine maleate, paroxetine hydrochloride hydrate, sertraline hydrochloride, escitalopram oxalate), serotonin-noradrenaline reuptake inhibitors (eg, milnacipran hydrochloride, duloxetine hydrochloride, venlafaxine hydrochloride), selective noradrenaline reuptake inhibitor (atomoxetine hydrochloride), noradrenergic and serotonergic antidepressant (mirtazapine), or central nervous system stimulants (eg, methylphenidate hydrochloride, lisdexamfetamine mesilate) [see Contraindications for Co-administration (Do not co-administered with the following.) under Interactions].
Patients with severe hepatic impairment (Child-Pugh C) [see Patients with Hepatic Impairment: Patients with severe hepatic impairment (Child-Pugh C) under Precautions].
Patients with a history of hypersensitivity to any of the ingredients of this drug.
Pregnant women or women suspected of being pregnant [see Use in Pregnancy & Lactation].